Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New virtual therapy aims to help dementia patients communicate better with loved ones

NCT ID NCT07219680

Symptom relief Sponsor: Maya Henry Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a personalized, virtual speech therapy program for people with primary progressive aphasia (a type of dementia that affects language) and their communication partners. The goal is to see if the program improves communication and quality of life. About 30 participants will either receive therapy right away or after a waiting period, and will complete assessments and questionnaires.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for Persons with PPA: * A PPA (Gorno-Tempini et al., 2011) or "PPA-plus" (Mesulam et al., 2001) diagnosis * MMSE score of 15 or higher and must be able to produce single monosyllabic words intelligibly * Must speak English, Spanish or both languages (i.e., bilingual speakers of English or Spanish) * Hearing and vision adequate for participation in teleconference meetings * Must have a study partner available (someone who will commit to attending teleconference sessions, as needed, during assessment and treatment phases) Inclusion criteria for Care Partners: * Partners must express willingness to attend and participate in assessment and treatment sessions, including those targeting dyadic communication goals * Partners must speak English, Spanish or both languages (i.e., bilingual speakers of English or Spanish) * Partner's hearing and vision should be adequate for participation in teleconference meetings The participant and/or study partner must have basic experience using a computer. Exclusion criteria for persons with PPA: * Other central nervous system or medical diagnosis that can account for symptoms * Psychiatric diagnosis that can account for symptoms

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Logopenic progressive aphasia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aphasia frontotemporal dementia logopenic progressive aphasia neurodegenerative disease primary progressive aphasia progressive non-fluent aphasia semantic dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Logopenic progressive aphasia Logopenic progressive aphasia (LPA) Logopenic variant of primary progressive aphasia (LPA) Logopenic variant primary progressive aphasia Nonfluent aphasia, progressive Nonfluent progressive aphasia Nonfluent variant primary progressive aphasia (nfvppa) Primary progressive aphasia(PPA) Progressive aphasia Semantic aphasia Semantic dementia Semantic variant primary progressive aphasia (svppa)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Texas

    RECRUITING

    Austin, Texas, 78712, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.